Assembly Biosciences
Update in progressASMB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Assembly Biosciences, Inc. is a biotechnology company developing antiviral therapeutics worldwide. Its pipeline includes long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 (Phase 1 for recurrent genital herpes) and ABI-6250, an oral HDV entry inhibitor in Phase 1a for chronic HDV. It also studies ABI-4334 (oral capsid assembly modulator, Phase 1b for chronic HBV) and ABI-7272 (oral broad-spectrum NNPI for transplant-associated herpesviruses). The company has an R&D option, license, and collaboration with Gilead. Based in South San Francisco, CA; incorporated in 2005.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Jason A. Okazaki J.D.
- Founded2005
- Employees73
- Websitewww.assemblybio.com